Success Metrics

Clinical Success Rate
93.8%

Based on 15 completed trials

Completion Rate
94%(15/16)
Active Trials
4(13%)
Results Posted
0%(0 trials)
Terminated
1(3%)

Phase Distribution

Ph phase_4
5
16%
Ph phase_3
5
16%
Ph not_applicable
7
23%
Ph phase_1
4
13%
Ph phase_2
10
32%

Phase Distribution

4

Early Stage

10

Mid Stage

10

Late Stage

Phase Distribution31 total trials
Phase 1Safety & dosage
4(12.9%)
Phase 2Efficacy & side effects
10(32.3%)
Phase 3Large-scale testing
5(16.1%)
Phase 4Post-market surveillance
5(16.1%)
N/ANon-phased studies
7(22.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.2%

15 of 17 finished

Non-Completion Rate

11.8%

2 ended early

Currently Active

4

trials recruiting

Total Trials

31

all time

Status Distribution
Active(6)
Completed(15)
Terminated(2)
Other(8)

Detailed Status

Completed15
unknown8
Recruiting4
Terminated1
Enrolling by invitation1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
31
Active
4
Success Rate
93.8%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (12.9%)
Phase 210 (32.3%)
Phase 35 (16.1%)
Phase 45 (16.1%)
N/A7 (22.6%)

Trials by Status

terminated13%
enrolling_by_invitation13%
completed1548%
withdrawn13%
recruiting413%
unknown826%
not_yet_recruiting13%

Recent Activity

Clinical Trials (31)

Showing 20 of 31 trialsScroll for more
NCT07572552Phase 2

Clinical Study Evaluating the Efficacy and Safety of Fenofibrates Versus Silymarin in Adult Patients With Sepsis

Not Yet Recruiting
NCT06922669Not Applicable

Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia

Recruiting
NCT07001150Phase 2

Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease

Recruiting
NCT07123922Not Applicable

Effect of Silymarin as Add on Therapy on Oxidative Stress, Pulmonary Function and Quality of Life in Stable COPD Patients.

Enrolling By Invitation
NCT06213857Phase 2

Beneficial Effect of Silymarin in Ulcerative Colitis

Recruiting
NCT06114719Phase 3

Silymarin for the Prevention of Atrial Fibrillation After Cardiac Surgery

Completed
NCT06425705Phase 2

Impact of Silymarin Adjunct Therapy on Proteinuria in Type 2 Diabetic Patients on RAS Inhibitors

Completed
NCT06277635Not Applicable

Effect of Silymarin Against Methotrexate-induced Liver Injury in Rheumatic Diseases

Recruiting
NCT05631041Phase 3

Effect of Silymarin in Metastatic Colorectal Cancer Patients

Unknown
NCT05595109Phase 2

Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients

Unknown
NCT04816682Phase 4

Silymarin in COVID-19 Patients Admitted to Hospital With Elevated Liver Enzymes

Completed
NCT03749070Not Applicable

Efficacy of Silymarin in Patients With Non-alcoholic Fatty Liver Disease - The SILIVER Trial

Unknown
NCT05099601Phase 4

Silymarin Cream Versus Combined Silymarin Cream and Microneedling in Treatment of Melasma

Unknown
NCT00755950Phase 2

Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis

Terminated
NCT04490967Phase 4

Silymarin Cream Versus Salicylic Acid in Treatment of Acne Vulgaris

Unknown
NCT02973295Phase 4

Silymarin in NAFLD

Withdrawn
NCT04394208Phase 3

Silymarin in COVID-19 Pneumonia

Unknown
NCT03130634Phase 4

The Efficacy of Silymarin as Adjuvant Therapy on Colorectal Cancer Patients Undergoing FOLFIRI Treatment

Completed
NCT03659058Not Applicable

Impact of Ursodeoxycholic Acid, Silymarin, Antioxidants and Colchicine on Fibrosis Regression in HCV After SVR

Completed
NCT01018615Phase 1

Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C

Completed

Drug Details

Intervention Type
DRUG
Total Trials
31